Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker: 2I9
München
16.11.26 | 08:02
0,018 Euro
0,00 % 0,000
1-Jahres-Chart
KDVENTURES AB Chart 1 Jahr
5-Tage-Chart
KDVENTURES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,03916.11.

Aktuelle News zur KDVENTURES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKDventures AB: KDventures' portfolio company SVF Vaccines enters research collaboration with Orexo to explore powder-based mRNA vaccine formulations343STOCKHOLM, Sweden, 11 November 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a research collaboration with Orexo AB (publ)...
► Artikel lesen
30.10.KDventures AB: KDventures portfolio company Umecrine Cognition reports results from Phase 1b/2a study of golexanolone in PBC - carrying value of holding to be adjusted to zero395STOCKHOLM, SWEDEN, October 30, 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) announces that its portfolio company Umecrine Cognition has reported topline results from the second part of its Phase...
► Artikel lesen
15.10.KDventures AB: John Öhd focuses on Modus Therapeutics and continues as Senior Advisor to KDventures182STOCKHOLM, Sweden, October 15, 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) today announces that John Öhd is transitioning from his role as Chief Scientific Officer (CSO) to Senior Advisor at...
► Artikel lesen
07.10.KDventures AB: KDventures portfolio company Umecrine Cognition invited to showcase Parkinson's disease program and new translational data at The Michael J. Fox Foundation's PDTC 2026250STOCKHOLM, Sweden, October 7, 2026. KDventures AB (publ) (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition AB ("Umecrine Cognition") will participate in The Michael...
► Artikel lesen
30.09.KDventures AB: KDventures' portfolio company AnaCardio raises EUR 62.5 million in Series B financing313STOCKHOLM, Sweden, September 30, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has entered into a EUR 62.5 million Series B financing. The financing...
► Artikel lesen
15.09.KDventures AB: KDventures' portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis272STOCKHOLM, Sweden, September 15, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has reported that the last patient has completed the final...
► Artikel lesen
KDVENTURES Aktie jetzt für 0€ handeln
07.09.KDventures AB: KDventures' portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds509STOCKHOLM, Sweden, September 7, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has received two Notices of Allowance from the United States...
► Artikel lesen
28.08.KDventures AB: Interim Report - January-June 2026295STOCKHOLM - 28 Augusti 2026. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Interim Report January-June 2026. The full report is available on the Company's website. "Following the acquisition...
► Artikel lesen
03.08.KDventures AB: KDventures' portfolio company Umecrine Cognition enrolls last patient in ongoing Phase 1b/2a study 248STOCKHOLM, Sweden, August 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has enrolled the last patient in the ongoing Phase 1b/2a study...
► Artikel lesen
12.05.KDventures AB: KDventures' Annual General Meeting 2026331STOCKHOLM, SWEDEN - May 12, 2026. KDventures AB (publ) ("KDventures" or the "Company") held the Annual General Meeting on May 12, 2026. The shareholders have had the right to exercise their voting rights...
► Artikel lesen
30.04.KDventures AB: Interim Report - January-March 2026370STOCKHOLM - 30 April 2026. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Interim Report January-March 2026. The full report is available on the Company's website. "We started 2026 by strengthening...
► Artikel lesen
09.04.KDventures AB: KDventures' portfolio company SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development352STOCKHOLM, Sweden, April 9, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a collaboration with Touchlight, a biotechnology company...
► Artikel lesen
11.03.KDventures AB: KDventures' portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval359STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering the use of AC01 for the treatment...
► Artikel lesen
03.03.KDventures AB: KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS537STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome...
► Artikel lesen
24.02.KDventures AB: KDventures's portfolio company SVF Vaccines announces that the intended merger with Novakand Pharma will not be carried out following negative decision from Nasdaq596STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed...
► Artikel lesen
13.02.KDventures AB: Year-end Report - January-December 2025406STOCKHOLM - 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. "A stronger financial...
► Artikel lesen
12.02.KDventures AB (publ): KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue425NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
10.02.KDventures AB (publ): KDventures' portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer495STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition...
► Artikel lesen
09.02.Change of issuer name and symbol for Karolinska Development AB515As from February 10, 2026, Karolinska Development AB will change issuer name and symbol. Old issuer name: Karolinska Development AB New issuer name: KDventures AB Old symbol: KDEV New symbol: KDV ISIN...
► Artikel lesen
06.02.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement444STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand...
► Artikel lesen
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1